‘This financing exceeded our objectives and was oversubscribed. We look forward to applying nearly all these funds to development of our lead medication candidates and medical device,’ said Don Wingerter, CEO of Ampio. The selling securityholders are under no obligation to market the common stock on efficiency of the registration statement.. Ampio raises $12.732 million through private keeping common stock Ampio Pharmaceuticals, Inc. announced today the successful completion of an exclusive placement that Ampio received gross proceeds of $12.732 million., New York, NY, acted as the placement agent in the supplying. The proceeds of the placement will be utilized to facilitate and additional the completion and evaluation of data for ongoing and multiple long term scientific trials, and for general corporate reasons.Cost of product sales for the fourth one fourth of 2011 was $485,000, in comparison to $498,000 in the same period this year 2010. Gross profit, as a % of revenue, for the three months ended December 31, 2011 and 2010 was 13 percent and 30 percent, respectively. This decrease is attributable to the shipment of MTWA Modules at no charge primarily. Operating expenses for the fourth quarter of 2011 were $1,382,000, a decrease of $59,000, or 4 percent, compared to $1,441,000 in the fourth quarter of 2010. The working loss for the 4th quarter of 2011 was $1,310,000 in comparison to an operating loss of $1,225,000 for the same period this past year. Contained in the operating loss for the fourth quarter of 2011 was $83,000 of noncash stock-based compensation expense, in comparison to $144,000 in the comparable 2010 period.